Grey-box pharmacokinetic/pharmacodynamic modelling of a euglycaemic clamp study
暂无分享,去创建一个
Henrik Madsen | Judith L. Jacobsen | H. Madsen | C. Tornøe | Christoffer Wenzel Tornøe | J. Jacobsen
[1] D. Howey,et al. Establishment of Time-Action Profiles for Regular and NPH Insulin Using Pharmacodynamic Modeling , 1994, Diabetes Care.
[2] M. Ramanathan. Pharmacokinetic Variability and Therapeutic Drug Monitoring Actions at Steady State , 2000, Pharmaceutical Research.
[3] D. Howey,et al. Comparative Pharmacokinetics and Glucodynamics of Two Human Insulin Mixtures 70/30 and 50/50 insulin mixtures , 1994, Diabetes Care.
[4] Lewis B. Sheiner,et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d‐tubocurarine , 1979 .
[5] H Derendorf,et al. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. , 1997, International journal of clinical pharmacology and therapeutics.
[6] David Z. D'Argenio,et al. Uncertain pharmacokinetic/pharmacodynamic systems: Design, estimation and control , 1997 .
[7] L. Skovgaard. NONLINEAR MODELS FOR REPEATED MEASUREMENT DATA. , 1996 .
[8] Murali Ramanathan,et al. An Application of Ito's Lemma in Population Pharmacokinetics and Pharmacodynamics , 1999, Pharmaceutical Research.
[9] C. Tornøe,et al. Grey-box PK/PD modelling of insulin , 2002 .
[10] J Pérez-Urizar,et al. Pharmacokinetic-pharmacodynamic modeling: why? , 2000, Archives of medical research.
[11] L B Sheiner,et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. , 1980, Clinical pharmacology and therapeutics.